| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 药品(元) | 549,628,007.00 | 802,641,204.23 | 375,542,276.23 | 531,529,198.98 | 239,318,417.23 |
| 医药中间体(元) | 943,345.15 | 273,341.36 | 92,706.80 | - | 1,332,442.79 |
| 资产租赁(元) | 45,871.56 | 22,935.78 | 15,290.52 | - | 45,871.56 |
| 经销授权许可(元) | - | 7,547,169.81 | - | - | - |
| 授权许可(元) | 654,762,347.72 | - | - | - | - |
| 营业成本(元) | |||||
| 药品(元) | 55,641,502.75 | 77,507,470.34 | 38,779,644.70 | 34,278,370.56 | 16,281,615.31 |
| 医药中间体(元) | 130,073.91 | 120,961.25 | 37,419.13 | - | 1,202,812.37 |
| 资产租赁(元) | 9,205.74 | 5,385.39 | 3,851.10 | - | 11,553.30 |
| 经销授权许可(元) | - | - | - | - | - |
| 授权许可(元) | 8,808,517.53 | - | - | - | - |
| 毛利(元) | |||||
| 药品(元) | 493,986,504.25 | 725,133,733.89 | 336,762,631.53 | 497,250,828.42 | 223,036,801.92 |
| 医药中间体(元) | 813,271.24 | 152,380.11 | 55,287.67 | - | 129,630.42 |
| 资产租赁(元) | 36,665.82 | 17,550.39 | 11,439.42 | - | 34,318.26 |
| 经销授权许可(元) | - | 7,547,169.81 | - | - | - |
| 授权许可(元) | 645,953,830.19 | - | - | - | - |
| 毛利率(%) | |||||
| 药品(%) | 89.88 | 90.34 | 89.67 | 93.55 | 93.20 |
| 医药中间体(%) | 86.21 | 55.75 | 59.64 | - | 9.73 |
| 资产租赁(%) | 79.93 | 76.52 | 74.81 | - | 74.81 |
| 经销授权许可(%) | - | - | - | - | - |
| 授权许可(%) | 98.65 | - | - | - | - |
| 收入构成(%) | |||||
| 药品(%) | 45.60 | 99.03 | 99.97 | 100.00 | 99.43 |
| 医药中间体(%) | 0.08 | 0.03 | 0.02 | - | 0.55 |
| 资产租赁(%) | 0.00 | 0.00 | 0.00 | - | 0.02 |
| 经销授权许可(%) | - | 0.93 | - | - | - |
| 授权许可(%) | 54.32 | - | - | - | - |
| 毛利构成(%) | |||||
| 药品(%) | 43.30 | 98.95 | 99.98 | 100.00 | 99.93 |
| 医药中间体(%) | 0.07 | 0.02 | 0.02 | - | 0.06 |
| 资产租赁(%) | 0.00 | 0.00 | 0.00 | - | 0.02 |
| 经销授权许可(%) | - | 1.03 | - | - | - |
| 授权许可(%) | 56.62 | - | - | - | - |